10-Q: InnovAge Reports Q2 Fiscal Year 2025 Results, Revenue Increases 10.6%

InnovAge Holding Corp. reports a 10.6% increase in revenue for the second quarter of fiscal year 2025, driven by growth in capitation revenue and member months.

Summary

• InnovAge Holding Corp. reported its financial results for the second quarter of fiscal year 2025, ended December 31, 2024.
• Total revenue increased by 10.6% to $209 million, compared to $188.9 million in the same period last year.
• Capitation revenue rose by 10.7% to $208.7 million, driven by a combination of increased capitation rates and a rise in member months.
• The company served approximately 7,480 PACE participants as of December 31, 2024.
• Operating loss was $12.6 million, compared to an operating loss of $1.8 million in the prior year.
• Net loss attributable to InnovAge Holding Corp. was $13.2 million, or $0.10 per share, compared to a net loss of $3.4 million, or $0.03 per share, in the prior year.
• The company recorded an impairment of right-of-use asset and construction in progress of $8.5 million related to halting developments to a previously planned de novo center in Louisville, Kentucky.
• The company repurchased 199,923 shares of its common stock for approximately $1.1 million during the quarter.
• On January 2, 2025, InnovAge completed the acquisition of certain pharmacy assets from Tabula Rasa HealthCare Group, Inc. for $4.8 million.

Sentiment

Score: 4

Explanation: The report shows revenue growth, but also increased losses and ongoing legal and regulatory challenges. The sentiment is neutral to slightly negative.

Positives

• Capitation revenue increased by 10.7% to $208.7 million, driven by a combination of increased capitation rates and a rise in member months.
• External provider costs decreased 3.1% in cost per participant for the three months ended December 31, 2024.
• On January 2, 2025, InnovAge completed the acquisition of certain pharmacy assets from Tabula Rasa HealthCare Group, Inc. for $4.8 million.

Negatives

• Operating loss was $12.6 million, compared to an operating loss of $1.8 million in the prior year.
• Net loss attributable to InnovAge Holding Corp. was $13.2 million, or $0.10 per share, compared to a net loss of $3.4 million, or $0.03 per share, in the prior year.
• The company recorded an impairment of right-of-use asset and construction in progress of $8.5 million related to halting developments to a previously planned de novo center in Louisville, Kentucky.

Risks

• The company is subject to ongoing civil investigative demands from the Attorney General for the State of Colorado and the Department of Justice.
• The company is involved in stockholder lawsuits alleging inaccurate and misleading statements and omissions in connection with the company's IPO and subsequent earnings calls and public filings.
• The healthcare sector continues to experience challenges in hiring additional professionals, leading to wage pressure.
• There is uncertainty regarding the access of participants to residential facilities.
• Delays and increased gaps in eligibility for new enrollments and Medicaid redetermination applications are being experienced.

Future Outlook

The company believes that its cash and cash equivalents, cash flows from operations, available funds, and access to financing sources will be sufficient to fund its operating and capital needs for the next 12 months and beyond.

Industry Context

The report highlights the challenges in the healthcare sector, including labor shortages and wage pressures, which are affecting InnovAge's cost of care. The company is also navigating regulatory scrutiny and legal proceedings, which are common in the healthcare industry.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the document does mention that InnovAge manages participants that are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in Medicare Advantage (MA) programs.
• As a result, InnovAge receives larger payments for its participants compared to MA participants.

Legal Proceedings

• The Company continues to fully cooperate with the Attorney General for the State of Colorado regarding a civil investigative demand.
• The Company and the DOJ have begun discussions to understand their respective positions on a civil investigative demand.
• The Company is fully cooperating with the DOJ and producing the requested information and documentation regarding a civil investigative demand related to the Company's relationship as a PACE provider with residential care facilities.
• The action is currently stayed as to WCAS Management Corporation, WCAS Management L.P., and WCAS Management, LLC but otherwise continues to be in discovery regarding stockholder lawsuits.
• On January 10, 2025, the District Court entered an amended order granting plaintiffs' motion to certify a class pursuant to the Federal Rules of Civil Procedure, Rule 23(b)(3).

Stakeholder Impact

• The company's performance and regulatory challenges could impact shareholders, employees, and participants in its PACE programs.
• The company's ability to provide quality care and manage costs will affect its relationships with government payors and other stakeholders.

Next Steps

• The company plans to continue investing in its centers, value-based care model, and sales and marketing organization to support long-term growth.
• The company intends to continue investing in resources and initiatives to provide necessary and quality services to its participants.

Key Dates